Antibodies that block the PDL1, PD1, or CTLA4 immune checkpoints are collectively termed “immune checkpoint blockade” (ICB), which is highly effective as cancer immunotherapy, but only in select patients [2,3,4,5]. This evidence concerns the gene CD274 and cancer.